Objective To evaluate the significance of serum colon cancer-specific antigen-2 (CCSA-2) in diagnosis
of colorectal cancer (CRC).
Methods By using ELISA method, the serum CCSA-2 was measured from 105 patients with 5 kinds of diseases, including CRC, gastric cancer, inguinal hernia, acute appendicitis, and breast cancer, who were
treated in our hospital from Jul. to Dec. in 2008, and 20 health donors were enrolled in addition. The blood samples were collected on 3 days before surgery, but blood samples from patients with acute appendicitis were collected before emergency
surgery, blood samples of health donors were collected on 1 day before ELISA test.
Results The level of serum CCSA-2 in CRC patients was (99.27±6.25) μg/L, which was significantly higher than those of other patients and health individuals〔(53.58±2.73) μg/L, t=48.29, P=0.000〕. Serum CCSA-2 at a cutoff of 73.96μg/L had a sensitivity of 100% (95% CI:100%-100%) and a specificity of 100% (95% CI:100%-100%) in separating CRC populations from all other indivi-duals by using receiver operator characteristic curve (ROC) analysis. As compared with carcinoembryonic antigen (CEA) and CA19-9, the serum CCSA-2 assay (at a cutoff of 73.96μg/L) was significantly more sensitive than CEA and CA19-9 assay in CRC detection (P<0.01). Serum CCSA-2 was not related with patients’ gender (P=0.81), age (P=0.59), TNM stage (P=0.85), Dukes stage (P=0.63), nuclear grade (P=0.44), as well as expressions of multidrug resistance associated protein (P=0.33), P-glycoprotein (P=0.72), and topoisomeraseⅡ(P=0.95), but higher in patients with colon cancer than those of patients with rectal cancer (P=0.02).
Conclusion Serum CCSA-2 may be a useful biomarker in diagnosis of CRC, and it may be only related to tumorigenesis, but is irrelated to tumor progression and chemotherapy.
Citation:
XUE Gang,ZHOU Jun,CAO Yongkuan,WANG Xiaojuan,YANG Yong,YANG Chaochun.. The Significance of Serum Colon Cancer-Specific Antigen-2 in Diagnosis of Colorectal Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(9): 1029-1033. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
1. |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
|
2. |
Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer[J]. CA Cancer J Clin, 2002, 52(1):8-22.
|
3. |
Markowitz SD, Bertagnolli MM. Molecular origins of cancer:molecular basis of colorectal cancer[J]. N Engl J Med, 2009, 361(25):2449-2460.
|
4. |
Cancer Research UK. By stage at diagnosis[EB/OL]. 2009-6-22.http://info. cancerresearchuk. org/cancerstats/types/bowel/survival/index. htmstage.
|
5. |
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4):225-249.
|
6. |
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med, 2004, 350(23):2343-2351.
|
7. |
Labianca R, Merelli B. Screening and diagnosis for colorectal cancer:present and future[J]. Tumori, 2010, 96(6):889-901.
|
8. |
Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011:a review of current American Cancer Society guidelines and issues in cancer screening[J]. CA Cancer J Clin, 2011, 61(1):8-30.
|
9. |
李岩. 合理应用结直肠癌血清肿瘤标志物的临床检测[J]. 中华医学杂志, 2008, 88(29):2023-2024.
|
10. |
Yeh CY, Hsieh PS, Chiang JM, et al. Preoperative carcinoembryonic antigen elevation in colorectal cancer[J]. Hepatogastroenterology, 2011, 58(109):1171-1176.
|
11. |
Hara M, Sato M, Takahashi H, et al. Accuracy of monitoringserum carcinoembryonic antigen levels in postoperative stageⅢcolorectal cancer patients is limited to only the first postoperative year[J]. Surg Today, 2011, 41(10):1357-1362.
|
12. |
Schmid G. The use of molecular markers in the diagnosis of colorectal cancer screening[J]. Dig Dis, 2010, 28(4-5):625-628.
|
13. |
Fey EG, Penman S. Nuclear matrix proteins reflect cell type of origin in cultured human cells[J]. Proc Natl Acad Sci U S A, 1988, 85(1):121-125.
|
14. |
徐建华, 林思远, 黄宪章, 等. 核基质蛋白在肿瘤研究中的应用[J]. 医学分子生物学杂志, 2008, 5(3):265-268.
|
15. |
黄金秀, 李恩民, 许丽艳. 核基质蛋白在肿瘤诊断中的应用[J]. 临床肿瘤学杂志, 2001, 6(4):382-383.
|
16. |
Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectalcancer-associated serum markers[J]. Cancer Res, 2007, 67(12):.
|
17. |
魏学明, 顾国利, 任力, 等. 多药耐药基因产物在胃癌组织中的表达及意义[J]. 中国普外基础与临床杂志, 2009, 16(12):1000-1004.
|
18. |
王佐正, 李明皓, 赵琳. MRP和P-gp在胰腺癌中的表达及其临床意义[J]. 宁夏医学杂志, 2012, 34(12):1199-1201.
|
19. |
Sodani K, Patel A, Kathawala RJ, et al. Multidrug resistance associated proteins in multidrug resistance[J]. Chin J Cancer, 2012, 31(2):58-72.
|
20. |
Sun YL, Patel A, Kumar P, et al. Role of ABC transporters in cancer chemotherapy[J]. Chin J Cancer, 2012, 31(2):51-57.
|
21. |
王雅琦, 王美鉴, 邱志敏, 等. P-糖蛋白在非霍奇金淋巴瘤组织中的表达及意义[J]. 实用癌症杂志, 2012, 27(6):583-585.
|
22. |
何迎盈, 刘娜娜, 罗治彬, 等. 阿苯达唑抑制P-糖蛋白表达对耐顺铂卵巢癌细胞耐药性的影响[J]. 第三军医大学学报, 2012, 34(17):1762-1765.
|
23. |
刘荣霞, 白江涛, 孙全昌, 等. Topo Ⅱ在大肠癌中的表达及意义[J]. 承德医学院学报, 2012, 29(3):237-239.
|
24. |
陈漫霞, 姚振江, 陈思东, 等. 原发性肝细胞癌中P-gp, TopoⅡα和P53的表达及意义[J]. 肿瘤防治研究, 2011, 38(3):278-.
|
25. |
, 285.
|
26. |
-5605.
|
- 1. Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
- 2. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer[J]. CA Cancer J Clin, 2002, 52(1):8-22.
- 3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer:molecular basis of colorectal cancer[J]. N Engl J Med, 2009, 361(25):2449-2460.
- 4. Cancer Research UK. By stage at diagnosis[EB/OL]. 2009-6-22.http://info. cancerresearchuk. org/cancerstats/types/bowel/survival/index. htmstage.
- 5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4):225-249.
- 6. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med, 2004, 350(23):2343-2351.
- 7. Labianca R, Merelli B. Screening and diagnosis for colorectal cancer:present and future[J]. Tumori, 2010, 96(6):889-901.
- 8. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011:a review of current American Cancer Society guidelines and issues in cancer screening[J]. CA Cancer J Clin, 2011, 61(1):8-30.
- 9. 李岩. 合理应用结直肠癌血清肿瘤标志物的临床检测[J]. 中华医学杂志, 2008, 88(29):2023-2024.
- 10. Yeh CY, Hsieh PS, Chiang JM, et al. Preoperative carcinoembryonic antigen elevation in colorectal cancer[J]. Hepatogastroenterology, 2011, 58(109):1171-1176.
- 11. Hara M, Sato M, Takahashi H, et al. Accuracy of monitoringserum carcinoembryonic antigen levels in postoperative stageⅢcolorectal cancer patients is limited to only the first postoperative year[J]. Surg Today, 2011, 41(10):1357-1362.
- 12. Schmid G. The use of molecular markers in the diagnosis of colorectal cancer screening[J]. Dig Dis, 2010, 28(4-5):625-628.
- 13. Fey EG, Penman S. Nuclear matrix proteins reflect cell type of origin in cultured human cells[J]. Proc Natl Acad Sci U S A, 1988, 85(1):121-125.
- 14. 徐建华, 林思远, 黄宪章, 等. 核基质蛋白在肿瘤研究中的应用[J]. 医学分子生物学杂志, 2008, 5(3):265-268.
- 15. 黄金秀, 李恩民, 许丽艳. 核基质蛋白在肿瘤诊断中的应用[J]. 临床肿瘤学杂志, 2001, 6(4):382-383.
- 16. Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectalcancer-associated serum markers[J]. Cancer Res, 2007, 67(12):.
- 17. 魏学明, 顾国利, 任力, 等. 多药耐药基因产物在胃癌组织中的表达及意义[J]. 中国普外基础与临床杂志, 2009, 16(12):1000-1004.
- 18. 王佐正, 李明皓, 赵琳. MRP和P-gp在胰腺癌中的表达及其临床意义[J]. 宁夏医学杂志, 2012, 34(12):1199-1201.
- 19. Sodani K, Patel A, Kathawala RJ, et al. Multidrug resistance associated proteins in multidrug resistance[J]. Chin J Cancer, 2012, 31(2):58-72.
- 20. Sun YL, Patel A, Kumar P, et al. Role of ABC transporters in cancer chemotherapy[J]. Chin J Cancer, 2012, 31(2):51-57.
- 21. 王雅琦, 王美鉴, 邱志敏, 等. P-糖蛋白在非霍奇金淋巴瘤组织中的表达及意义[J]. 实用癌症杂志, 2012, 27(6):583-585.
- 22. 何迎盈, 刘娜娜, 罗治彬, 等. 阿苯达唑抑制P-糖蛋白表达对耐顺铂卵巢癌细胞耐药性的影响[J]. 第三军医大学学报, 2012, 34(17):1762-1765.
- 23. 刘荣霞, 白江涛, 孙全昌, 等. Topo Ⅱ在大肠癌中的表达及意义[J]. 承德医学院学报, 2012, 29(3):237-239.
- 24. 陈漫霞, 姚振江, 陈思东, 等. 原发性肝细胞癌中P-gp, TopoⅡα和P53的表达及意义[J]. 肿瘤防治研究, 2011, 38(3):278-.
- 25. , 285.
- 26. -5605.